FRE GR

Fresenius SE & Co. KGaA

Healthcare


Presented:08/22/2024
Price:€32.54
Cap:$20.41B
Current Price:€33.73
Cap:$21.16B

Presented

Date08/22/2024
Price€32.54
Market Cap$20.41B
Ent Value$31.97B
P/E RatioN/A
Book Value€33.79
Div Yield0%
Shares O/S563.24M
Ave Daily Vol1,005,594
Short IntN/A

Current

Price€33.73
Market Cap$21.16B
Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment caters to individuals with renal diseases. The Fresenius Kabi segment specializes in lifesaving medicines and technologies. The Fresenius Helios offers expertise in inpatient and outpatient care as well as in telemedicine. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The company was founded by Eduard Fresenius on October 1, 1912 and is headquartered in Bad Homburg, Germany.

Publicly traded companies mentioned herein: Fresenius SE & Co KGaA (FRE GR)

Highlights

The presenter is long shares Fresenius SE & Co KGaA (FRE GR). After years of underperformance, the company has simplified its complex business structure under a new CEO, which has reduced costs and simplified the story for investors. Additionally, Fresenius's biosimilars business is set to break even this year and potentially see revenues triple over the coming years. Applying an 8.5x EBITDA multiple, the presenter's calculations suggest 60% upside with incremental upside if the company continues to execute and improves FCF generation.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.